Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Rating of “Buy” from Brokerages

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has received an average rating of “Buy” from the six brokerages that are currently covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $29.50.

Several research analysts have commented on CPRX shares. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Citigroup upped their target price on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Oppenheimer reissued an “outperform” rating and issued a $29.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, June 6th. Truist Financial increased their price objective on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, HC Wainwright boosted their target price on Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, August 12th.

Catalyst Pharmaceuticals Stock Down 2.6 %

Shares of NASDAQ:CPRX opened at $20.79 on Monday. The firm has a market capitalization of $2.46 billion, a PE ratio of 38.50, a P/E/G ratio of 3.10 and a beta of 0.75. The company has a 50-day moving average price of $18.90 and a two-hundred day moving average price of $16.82. Catalyst Pharmaceuticals has a twelve month low of $11.55 and a twelve month high of $21.67.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.13. The business had revenue of $122.71 million during the quarter, compared to analyst estimates of $111.76 million. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. Analysts anticipate that Catalyst Pharmaceuticals will post 1.82 earnings per share for the current fiscal year.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 150,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the completion of the sale, the insider now owns 675,124 shares of the company’s stock, valued at $13,738,773.40. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Catalyst Pharmaceuticals news, insider Steve Miller sold 150,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the transaction, the insider now directly owns 675,124 shares of the company’s stock, valued at $13,738,773.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David S. Tierney sold 15,000 shares of the company’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the completion of the sale, the director now directly owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. The disclosure for this sale can be found here. Insiders have sold a total of 201,058 shares of company stock valued at $4,018,188 over the last 90 days. 11.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of CPRX. GAMMA Investing LLC increased its stake in Catalyst Pharmaceuticals by 72.9% in the 1st quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 819 shares during the period. CWM LLC raised its holdings in Catalyst Pharmaceuticals by 686.5% during the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 3,549 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in Catalyst Pharmaceuticals during the 2nd quarter valued at $70,000. Headlands Technologies LLC bought a new stake in Catalyst Pharmaceuticals in the 1st quarter worth $154,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Catalyst Pharmaceuticals in the 2nd quarter worth $153,000. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.